Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Enfoque percutáneo para reducir los efectos de la regurgitación tricuspídea grave

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOSG20171107002
Publicado:
07/11/2017
Caducidad:
07/11/2018
Resumen:
Un centro de investigación de Singapur ha desarrollado una nueva solución para el tratamiento percutáneo de pacientes con regurgitación tricuspídea grave. Esta solución se ha desarrollado para evitar los retos implicados en la visualización y anclaje de dispositivos percutáneos en el anillo nativo. La tecnología se encuentra en fase preclínica. El centro de investigación busca socios industriales (pymes y multinacionales) en el sector de dispositivos médicos de clase III con el fin de mejorar la tecnología y establecer acuerdos de licencia y cooperación en materia de investigación.

Details

Tittle:
Percutaneous approach to mitigate effects of severe tricuspid regurgitation.
Summary:
A Singapore research institution has developed a novel solution to percutaneously treat patients suffering from severe Tricuspid Regurgitation. It is aimed at circumventing the challenges involved in the accurate visualisation and anchorage of percutaneous devices at the native annulus site. At pre-clinical trial phase, the institution seeks interested industry partners - SMEs/MNEs in the class III medical devices sector to move the technology forward through licensing/research cooperation.
Description:
Tricuspid Regurgitation (TR) refers to the backflow of blood from the right ventricle to the right atrium due to the malfunction of the tricuspid valve. The high venous backflow pressure leads to damage to vital organs such as the liver. Left untreated, 1 in 2 patients with moderate to severe TR will die within 4 years.

Currently, TR ranks the second most common but most untreated disease in the United States due to a very high operative risk, where morbidity rate is 22%. This is in part due to the complex nature of surgical intervention at the tricuspid valve as well as the age group of the patients undergoing the procedure. While percutaneous therapies have been introduced for other valve pathologies, such as the aortic and mitral valve, there is no clinically available treatment for severe TR, due to the complex geometry of the tricuspid valve and the lack of anchoring zone.

The Singapore research institution has developed a solution that has been proven in animal trials to prevent high systolic pressures to be transmitted distally to the end organs, permit improved forward flow and translate into improved symptoms.

The research institution is interested in establishing license agreements or research cooperation agreements with a partner from the healthcare industry, such as an SME of any size or MNEs in the class III medical devices sector for further development or commercialisation of this technology.
Advantages and Innovations:
The technology offers the following advantages:

- Completely percutaneous intervention. This provides a treatment option to patients suffering from severe TR that were previously precluded from surgery due to elevated mortality risks.

- Self-alignment feature during device deployment grants reproducible accuracy, confidence and device efficacy.

- Delivery system with feedback mechanism allows to minimise the use of intra-procedural x-ray imaging that may be harmful to both patient and clinician.

· Design of the device proven to promote rapid endothelialisation.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Patent applied for Singapore

Partner sought

Type and Role of Partner Sought:
The healthcare research institution seeks to work with SMEs of all sizes or MNEs, including hospitals in a licensing or research cooperation agreement partnership.

Under a licensing agreement:
The partner can license the technology to offer as a product or service to their customers/patients.

Under a research cooperation agreement:
The partner can undertake joint development with the Singapore research institution to further develop this technology to targeted markets/segments.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English

Keywords

Technology Keywords:
06001013 Tecnología médica / ingeniería biomédica